Protagonist leverages its proprietary peptide technology platform to discover and develop novel drug candidates that can transform the existing treatment paradigms in diseases with significant unmet medical needs.
PTG-300 is a mimetic of the natural hormone hepcidin that is currently in a phase 2 study in polycythemia vera (PV), a rare blood disorder, and a phase 2 study in hereditary hemochromatosis (HH), a blood disorder arising from absence or deficiency of hepcidin gene. Hepcidin is a master regulator of iron homeostasis and controls the absorption, storage, and distribution of iron in the body.